Research programme: MM 111 companion diagnostic - Merrimack Pharmaceuticals
Latest Information Update: 13 Mar 2015
At a glance
- Originator Merrimack Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 26 Feb 2015 Discontinued - Preclinical for Solid tumours (Diagnosis) in USA (unspecified route)
- 30 Mar 2012 Preclinical trials in Solid tumours (Diagnosis) in USA (unspecified route)